A Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with Sunitinib

The article discusses sunitinib (Pfizer) for the treatment of medullary thyroid carcinoma. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers. Context. Medullary thyroid carcinoma (MTC) is a neu-roendocrine tumor arising from “C ” cells of the thy-roid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the ge-netic changes associated with the development of MTC explain the growing interest in the therapeutic potential of tyrosine kinase inhibitors. Sunitinib is an orally ad-ministered multikinase inhibitor likely to target multi-ple pathways in the tumor, stromal, and endothelial compartments. Its role in the treatment of MTC pa